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Objective: Oxidative stress contributes to myocardial ischemia-reperfusion injury.
We hypothesized that administration of the antioxidant N-acetylcysteine would have
beneficial effects on myocardial function after cardiopulmonary bypass and car-
dioplegic arrest.
Methods: Anesthetized dogs (n 18) were instrumented with myocardial ultrasonic
crystals and a left ventricular micromanometer. Systolic function was measured by
preload recruitable stroke work. Myocardial tissue water was determined by micro-
gravimetry. Treated animals received 100 mg · kg1 N-acetylcysteine 10 minutes
before initiation of cardiopulmonary bypass followed by 20 mg · kg1 · h1
continuous infusion until 1 hour after cardiopulmonary bypass. After baseline,
cardiopulmonary bypass and 2-hour crystalloid cardioplegic arrest was initiated,
then reperfusion/rewarming for 40 minutes and separation from cardiopulmonary
bypass. Myocardial function parameters and myocardial tissue water were measured
at 30, 60, and 120 minutes after cardiopulmonary bypass. Oxidative stress was
measured by 8-isoprostane concentrations in the coronary sinus plasma.
Results: Preload recruitable stroke work did not decrease from baseline in the
N-acetylcysteine group and was significantly greater in N-acetylcysteine group
compared with controls at 30 (104% 9% vs 80% 4%; P .05) and 120 minutes
(98%  7% vs 79%  4%; P  .05) after cardiopulmonary bypass. Concentrations of
8-isoprostane in the coronary sinus plasma of the control dogs were significantly higher
30 minutes after cardiopulmonary bypass compared with baseline but were unchanged
in the N-acetylcysteine group. Myocardial edema resolution was significantly greater in
the N-acetylcysteine group at 30 minutes after cardiopulmonary bypass compared with
control (2.5%  0.7% vs 0.3%  0.5% myocardial tissue water; P  .05).
Conclusions: Administration of the antioxidant N-acetylcysteine preserves systolic
function and enhances myocardial edema resolution after cardiopulmonary bypass/
cardioplegic arrest. Furthermore, oxidative stress was significantly reduced in the
treated animals. Therefore, our findings support the hypothesis that oxidative stress
is the main cause for myocardial dysfunction after ischemia-reperfusion.
Myocardial protection during cardiopulmonary bypass (CPB)and cardioplegic arrest (CA) has continued to be refined sinceits introduction.1 Despite numerous advances the heart maystill exhibit evidence of ischemia-reperfusion injury, such asarrhythmias, microvascular damage, edema, myocardial stun-ning, and cell death.2,3 A mechanism by which ischemia-
reperfusion may produce these findings is the generation of reactive oxygen species
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(ROS), which has been shown to form during the early
phase of reperfusion.4,5 The alterations in membrane per-
meability, configuration, and cellular proteins due to ROS
have been suggested as a main cause for ischemia-reperfu-
sion injury.6 To eliminate or at least diminish the effects of
ROS associated with CPB/CA, several studies have been
performed using antioxidants.7-12 The results are inconclu-
sive, most likely due to factors such as species differences,
different experimental methods, and different types of an-
tioxidants.
After examination of the literature we chose N-acetyl-
cysteine (NAC) as a nonspecific antioxidant for our study.
NAC interacts with oxygen radicals and results in NAC-
disulfide as a main end product.13 In addition to its function
as oxygen radical scavenger, NAC also inhibits oxygen
radical generation by polymorphonuclear leukocytes in
vitro and in vivo.14,15
The effect of NAC on reperfusion injury in a number of
experiments including CPB has been investigated.
Andersen and colleagues7 showed that NAC significantly
diminished neutrophil oxidative burst response throughout
CPB. Another study reported that NAC could prevent sec-
ondary lung reperfusion injury after liver ischemia-reperfu-
sion.16 Furthermore, NAC prevented radiographic contrast-
agent–induced reductions in renal function due to ROS.17
Thus, NAC appears to be a promising substance for reduc-
tion of oxidative stress related to CPB/CA.
The purpose of our study was to evaluate the effect of
NAC administration on ROS-mediated ischemia-reperfu-
sion injury associated with CPB/CA. Therefore, we chose to
measure preload recruitable stroke work (PRSW) and myo-
cardial tissue water (MWC) as depressed left ventricular
(LV) function and myocardial edema are major components
of ischemia-reperfusion injury.3 We hypothesized that NAC
would preserve myocardial function after CA and CPB by
oxidative stress reduction.
Methods
Animal Preparation
All procedures were approved by the University of Texas Animal
Welfare Committee. Eighteen conditioned mongrel dogs of either
sex (29.2  3.4 kg) were anesthetized with 25 mg/kg thiopental
sodium intravenously and endotracheally intubated. The lungs
were mechanically ventilated with 100% oxygen using a volume-
cycled ventilator (Servo ventilator 900C, Siemens-Elema, Solna,
Sweden). Anesthesia was maintained with an intravenous infusion
of 1% thiopental sodium in lactated Ringer’s solution.
Fluid-filled catheters were inserted in the left femoral artery
and vein for mean arterial pressure monitoring, arterial blood
sampling, and fluid administration. A Swan-Ganz catheter (Ed-
wards LifeSciences, Irvine, Calif) was inserted via the right jugular
vein into the pulmonary artery for central venous pressure, pul-
monary artery pressure (PAP), pulmonary artery wedge pressure
(PCWP), and cardiac output (CO) determinations. The pressure-
monitoring catheters were connected to calibrated pressure trans-
ducers (Isotec, Healthdyne Cardiovascular, Irvine, Calif) and data
were recorded on a computer (MacLab, WorldPrecision Instru-
ments, Sarasota, Fla). The right femoral artery was exposed for
subsequent CPB cannulation. After a median sternotomy and peri-
cardiotomy, a 7F catheter was placed into the coronary sinus for
coronary sinus blood sampling. Subsequently we placed sonomi-
crometry crystals (10 MHz, Sonometrics, London, Ontario, Can-
ada) in the subendocardium at midventricular level across the
septum/free wall axis of the left ventricle. A micromanometer-
tipped pressure transducer (Millar Instruments Inc, Houston, Tex)
was introduced in the LV cavity through the apex. We placed a
snare around the inferior vena cava for cardiac preload manipula-
tion. PRSW was determined according to Glower and colleagues18
using a software package (Sonometrics, London, Ontario, Can-
ada).
CPB and Cardioplegic Arrest
After preparation, heparin (250 IU/kg) was given intravenously for
systemic anticoagulation. Additional doses of 75 IU/kg heparin
were administered every 60 minutes throughout the experiment. A
16F arterial perfusion cannula was introduced into the prepared
right femoral artery. A 2-stage (34F/38F) venous cannula was
placed into right atrium/inferior vena cava. The LV chamber was
vented with a 12F catheter inserted via the left atrium. Three roller
pumps were used for extracorporeal circulation, left ventricular
drainage, and suction (Sarns Inc, Ann Arbor, Mich). The extra-
corporeal circuit and the membrane oxygenator (Cobe Cardiovas-
cular Inc, Arvada, Colo) were primed with 1000 mL of lactated
Ringer’s solution and 1000 IU of heparin. In 9 dogs (group NAC)
10 minutes before initiation of CPB, NAC (Sigma Chemical Co, St
Louis, Mo) was dissolved in 0.9% NaCL and administered intra-
venously as a bolus of 100 mg/kg (50 mg/mL) followed by an
infusion of 20 mg/kg per hour (50 mg/mL).7,16 In 9 dogs that
served as controls (group CON), the same fluid amount without
NAC was applied. The body temperature was cooled to 28°C. The
aorta was crossclamped, and 500 mL iced (approximately 4°C)
crystalloid cardioplegic solution (Plegisol; Abbott Laboratories,
Chicago, Ill) was infused into the aortic root at 80 mm Hg. An
additional 100 mL of cardioplegic solution was given after 60
minutes of cardiac arrest or if electrical or mechanical activity of
the heart occurred. There was no difference concerning the amount
of administered cardioplegic solution between the groups. Whole-
body hypothermia at 28°C was maintained for 105 minutes of
aortic crossclamping, followed by rewarming to 37°C. After 120
minutes of CA, the aortic crossclamp was removed, and the heart
was reperfused on normothermic CPB for 40 minutes. The dogs
were weaned from CPB and all cannulas were removed. We kept
CPB flow between 40 and 60 mL · kg1 · min1 to maintain a
systemic perfusion pressure of 40 to 70 mm Hg. No inotropic or
antiarrythmic agents were required for separation from CPB or in
the post-CPB period. In the NAC group, NAC infusion was
continued until 60 minutes after CPB.
Insterstitial Myocardial Edema
Myocardial water content was measured from endomyocardial
biopsies using microgravimetric technique as previously de-
scribed.19 In brief, a linear density gradient was prepared in a
gradient former from 2 different mixtures of kerosene and bromo-
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benzene, which were adjusted to a specific gravity of 0.990 and
1.080, respectively. The gradient was calibrated with various
K2SO4 solutions with known specific gravities and by recording
the equilibration depth of 10 L drops of the various solutions.
Linearity of the gradient was confirmed by linear-square regres-
sion analysis after plotting the equilibration depths versus specific
gravity. The mean correlation coefficient was 0.96  0.008 (n 
18). To determine the specific gravity of myocardium, we intro-
duced an endoluminal biopsy forceps transapically into the left
ventricle and collected myocardial samples. These samples were
placed gently into the density column and the equilibration depth
was recorded after 1 minute. MWC can be calculated using the
equation: MWC (1[(SGmyo 1)/(1 1/SGdry) SGmyo])
100 (%), where SGmyo and SGdry are the specific gravities of the
myocardial tissue and dry myocardium, respectively. On conclu-
sion of the experiment, the dog was killed with an intravenous
overdose of thiopental sodium (Pentothal) and saturated potassium
chloride. After a last myocardial tissue density measurement, the
heart was rapidly excised. The right and left ventricle were then
weighed and dried at 60°C in an oven to a constant weight. We
assume that SGdry did not change over the experimental period.
Edema resolution was defined as decrease in MWC 2 hours after
CA.
8-Isoprostane Determination in Coronary Sinus
Plasma
To evaluate the ROS-mediated tissue injuries we used an assay of
8-iso-prostaglandin-F2 (8-isoprostane)20; 8-isoprostane is the sta-
ble end product of arachidonic acid oxidation generated by ROS
injury to membrane phospholipids21 and has been used as an
indicator for free radical–mediated injury in hearts of patients
subjected to cardioplegia.22 The concentration of 8-isoprostane
was measured in coronary sinus plasma using a kit (Cayman
Chemical Company, Ann Arbor, Mich).
Experimental Protocol
After instrumentation, we recorded baseline measurements of CO,
mean arterial pressure, PAP, PCWP, central venous pressure, and
LV pressure-volume loops. Two myocardial samples for MWC
determination were collected. We placed the dog on CPB and
initiated cardiac arrest as described above. We measured all vari-
ables at 30, 60, 90, and 120 minutes during cardiac arrest. At 30,
60, and 120 minutes after separation from CPB we repeated all
measurements. Myocardial samples were taken parallel to all mea-
surements.
Statistical Analysis
We examined the time courses of each measured parameter using
analysis of variance for repeated measures and the Student t test
for comparisons between the groups. Post hoc comparisons were
performed using the Tukey test.
Results
Hemodynamic Parameters
Heart rate (HR) was significantly increased in the CON
group in the post-CPB period compared with baseline,
whereas HR remained stable in the NAC group. Mean
arterial pressure was significantly decreased in both groups
after weaning from CPB compared with baseline values, but
remained stable thereafter. Cardiac index did not change in
either group (see Table 1).
Contractile Function
After weaning from CPB, the PRSW values in the NAC
group did not change compared with baseline. In the control
group, PRSW was significantly decreased compared with
baseline and was significantly lower at 30 and 120 minutes
after CPB compared with the NAC group (Table 1).
Isovolumic Relaxation
In both groups  was increased with myocardial edema
formation after CPB but was only significant in the NAC
group at 60 minutes after CPB; rate of pressure rise (dP/
dtmax) was significantly decreased in both groups after
weaning from bypass compared with baseline values and
did not recover with edema resolution within 120 minutes
after CPB (Table 1).
Myocardial Water Content
In both groups MWC increased after initiation of cardiac
arrest by Plegisol administration (Table 1). After weaning
from CPB, myocardial edema resolved but was still signif-
icant 120 minutes after CPB compared with baseline in
either group. However, edema resolution 30 minutes as
measured by decrease in MWC after weaning from CPB
was significantly higher in the NAC group compared with
the CON group (Figure 1).
8-Isoprostane Concentrations in the Coronary Sinus
Plasma
The concentration of 8-isoprostane in the coronary sinus
plasma of the control dogs was significantly higher at 30
minutes after CPB compared with baseline (223%  97%;
P  .05) and with the NAC group. Values of 8-isoprostane
in the NAC group were not significantly changed compared
with baseline levels (89%  50%; see Figure 2).
Discussion
Our data show that NAC administration during CPB and
CA preserved LV function and improved myocardial edema
resolution in the early phase after weaning from CPB.
LV Function
We believe that the preserved LV systolic function in the
NAC group is due to the ROS reduction during CPB and
especially during the early reperfusion period. Increased
generation of ROS results in alterations of membrane per-
meability, configuration, and cellular proteins, which in turn
are responsible for LV systolic dysfunction as part of isch-
emia-reperfusion damages to the heart.6 A reduction of the
ROS generation during CPB and especially during reperfu-
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sion is therefore most likely the explanation for the pre-
served LV systolic function in the NAC group.
Although oxidative stress is the main cause for ischemia-
reperfusion injury,5 a beneficial effect of antioxidants on
cardiac ischemia-reperfusion injury could not be shown for
all agents used in previous studies.11 These inconsistent
findings could be due to study differences. We chose to
administer NAC over the whole period of CPB until 60
minutes after weaning from CPB because CPB itself is
associated with oxidative stress. Compared with other stud-
ies, the protective effect covered the whole CPB and reper-
fusion period, suggesting that an extended protection
against oxygen radicals is more efficient in reducing oxida-
tive stress and preserving cardiac function.
The type of antioxidant has also been suggested to be
responsible for controversial effects on myocardial perfor-
mance after ischemia-reperfusion.3
Some of the beneficial effects of NAC have been attrib-
uted to its chemical structure that includes a thiol-containing
compound. In studies with CPB and ischemic precondition-
ing, thiol-containing compounds have been shown to be
beneficial and have been suggested as potent defense sys-
tems against ischemia-reperfusion–related oxidative stress.3
We know that the NAC dose used in this study was
sufficient, as evidently 8-isoprostane concentrations were
unchanged in the treated dogs compared with baseline,
which is consistent with the findings of Andersen and col-
leagues.7
Myocardial Edema Resolution
The significantly higher decrease in MWC during the first
30 minutes after CPB and therefore improved edema reso-
lution in the NAC group could be due to the following
reasons. Allen and coworkers23 showed that augmented
TABLE 1. Hemodynamic parameters, left ventricular diastolic function, and myocardial water content
Baseline
30 minutes
post-CPB
60 minutes
post-CPB
120 minutes
post-CPB
HR (bpm)
CON 126 14 144 13* 145 12* 135 14*
NAC 133 11 138 15 138 15 126 15
MAP (mm Hg)
CON 122 12 82 13* 82 9* 96 17*
NAC 118 22 89 9* 86 10* 91 11*
CVP (mm Hg)
CON 9 3 10 2 9 2 9 2
NAC 7 1 8 1*,† 8 1*,† 8 1*,†
PAP (mm Hg)
CON 19 4 21 4 23 4* 23 6*
NAC 16 3 21 2* 21 1* 21 2*
PCWP (mm Hg)
CON 10 3 13 6* 12 4* 14 4*
NAC 9 3 11 2 10 2 10 4†
Cardiac index (L/min per m2)
CON 3.08 0.87 3.19 1.63 3.35 2.34 2.87 1.45
NAC 3.26 1.53 3.05 1.39 2.87 1.88 2.25 1.17
 (ms)
CON 45 13 47 15 49 13 41 12
NAC 40 9 48 20 51 20* 45 15
dP/dtmax (mm Hg/s)
CON 1916 432 1373 520* 1320 508* 1235 269*
NAC 1886 433 1168 226* 1185 302* 1099 456*
MWC (%)
CON 79.35 2.25 82.03 1.93* 81.14 3.25* 80.23 2.82*
NAC 77.57 0.69 81.19 1.41* 80.79 1.40* 80.37 1.18*
PRSW (% bl) (mm Hg)
CON 80 14*,† 85 15* 79 10*,†
71.1 13.4 56.3 10.2 59.8 10.2 55.9 15.8
NAC 104 29 98 20 98 21
58.0 6.2 60.1 15.1 57.8 10.7 56.7 11.6
Values are mean  standard deviation. HR, Heart rate; CI, cardiac index; MAP, mean arterial pressure; PAP, pulmonary artery pressure; CVP, central
venous pressure; PCWP, pulmonary capillary wedge pressure; , isovolumic relaxation constant; dP/dtmax, pressure at negative dP/dtmax; MWC,
myocardial water content; PRSW, preload recruitable stroke work; CPB, cardiopulmonary bypass.
*P  .05 for difference from baseline period.
†P  .05 for difference between the groups.
Cardiopulmonary Support and Physiology Fischer et al
1486 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
CSP
contractility hastens myocardial edema resolution. The pre-
served contractility after weaning from CPB in the NAC
group could explain the better edema resolution compared
with control.
Differences in edema resolution between the groups
could also be explained by impaired myocardial lymphatic
function due to increased ROS concentration during the
early phase of reperfusion in the control group. Oxidative
stress has been shown to impair lymphatic function.24,25
The changes in edema resolution between the groups could
only be found within 30 minutes after CPB. In this period
the oxidative stress as measured by 8-isoprostane concen-
trations in the coronary sinus plasma was still higher in the
CON group compared with NAC. Thus, impaired lymphatic
function due to increased ROS concentration might have
contributed to a slower edema resolution in the CON group.
Myocardial edema was not completely resolved at the
end of the experiment in either group and therefore explains
the impaired diastolic function as measured by  and dP/
dtmax.
Additional Effects of NAC
According to Andrews and colleagues,26 NAC improves
coronary vascular function as measured by coronary artery
flow. We did not investigate possible differences in coro-
nary vascular flow between the NAC and CON groups. As
oxidative stress is the main cause for ischemia-reperfusion
injury, we believe that NAC functioned mainly as antioxi-
dant. However, an improved vascular function in the NAC
group may have contributed to preserve myocardial func-
tion.
Clinical Implications
Although it is uncertain whether our findings can be extrap-
olated to clinical situations, we believe that the animal data
is strong enough to warrant the consideration of a clinical
trial because beneficial effects of NAC on myocardial func-
tion after CPB and CA have been shown in other species.3
Andersen and coworkers7 showed that NAC in the dosage
we used in our study reduced the neutrophil oxidative
response during CPB in patients undergoing coronary artery
bypass surgery without adverse effects. In our study we also
did not see any adverse effects. Whether this concentration
is also sufficient to depress the oxidative burst at the begin-
ning of reperfusion after CA in patients has to be evaluated.
However, even higher NAC concentrations could be used
with little risk of adverse effects.27,28 Furthermore, NAC in
equal or even higher doses has been successfully used in
clinical studies for the treatment of acute myocardial infarc-
tion.29,30
Our findings and the clinical studies using NAC in the
context of local ischemia-reperfusion demonstrate that NAC
administration improves myocardial performance and sig-
nificantly diminishes oxidative stress after cardiac surgery
with CPB and CA. Therefore, we believe that clinical stud-
ies using NAC in the context of CPB and CA are warranted.
We thank Cobe Cardiovascular Inc for their generous support
by providing the cardiopulmonary bypass sets.
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